A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer.
- Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), C/Melchor Fernandez Almagro 3, 28029, Madrid, Spain.
- CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
- ARC-Net Centre for Applied Research on Cancer and Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy.
- CIBERONC, Madrid, Spain.
- Madrid-Norte-Sanchinarro Hospital, Madrid, Spain.
- Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
- Gastrocentrum, Karolinska Institutet and University Hospital, Stockholm, Sweden.
- Department of Surgery, Technical University of Munich, Munich, Germany.
- Department of Surgery, Hospital 12 de Octubre, and Department of Surgery and Health Research Institute, Fundación Jiménez Díaz, Madrid, Spain.
- Centre for Public Health, Queen's University Belfast, Belfast, UK.
- Molecular Genetics Laboratory, General University Hospital of Elche, Elche, Spain.
- Department of Medicine, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
- Department of Gastroenterology and Clinical Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Barts Cancer Institute, Centre for Molecular Oncology, Queen Mary University of London, London, UK.
- Department of Gastroenterology, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
- Department of Gastroenterology, University Hospital of Giessen and Marburg, Marburg, Germany.
- Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
- National Cancer Registry Ireland and HRB Clinical Research Facility, University College Cork, Cork, Ireland.
- Centre for Stem Cell Research and Developmental Biology, University of Copenhagen, Copenhagen, Denmark.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stokholm, Sweden.
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- CIBERESP, Madrid, Spain.
- Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA.
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
- International Agency for Research on Cancer (IARC), Lyon, France.
- Deparment for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
- Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA.
- Genomic Epidemiology Group, German Cancer Research Center (DKFZ, Heidelberg, Germany.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
- Departments of Medicine, Brigham and Women's Hospital, VA Boston and Harvard Medical School, Boston, MA, USA.
- SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
- Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
- University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
- Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA.
- Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
- Escuela Andaluza de Salud Pública (EASP), Granada, Spain.
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
- Department Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
- Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- National Centre for Genomic Analysis (CNAG), Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Universitat Pompeu Fabra (UPF), ICREA, Baldiri Reixac 4, 08028, Barcelona, Spain. martirenom@cnag.crg.eu.
- Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), C/Melchor Fernandez Almagro 3, 28029, Madrid, Spain. nmalats@cnio.es.
BACKGROUND: Pancreatic cancer (PC) is a complex disease in which both non-genetic and genetic factors interplay. To date, 40 GWAS hits have been associated with PC risk in individuals of European descent, explaining 4.1% of the phenotypic variance.
METHODS: We complemented a new conventional PC GWAS (1D) with genome spatial autocorrelation analysis (2D) permitting to prioritize low frequency variants not detected by GWAS. These were further expanded via Hi-C map (3D) interactions to gain additional insight into the inherited basis of PC. In silico functional analysis of public genomic information allowed prioritization of potentially relevant candidate variants.
RESULTS: We identified several new variants located in genes for which there is experimental evidence of their implication in the biology and function of pancreatic acinar cells. Among them is a novel independent variant in NR5A2 (rs3790840) with a meta-analysis p value = 5.91E-06 in 1D approach and a Local Moran's Index (LMI) = 7.76 in 2D approach. We also identified a multi-hit region in CASC8-a lncRNA associated with pancreatic carcinogenesis-with a lowest p value = 6.91E-05. Importantly, two new PC loci were identified both by 2D and 3D approaches: SIAH3 (LMI = 18.24), CTRB2/BCAR1 (LMI = 6.03), in addition to a chromatin interacting region in XBP1-a major regulator of the ER stress and unfolded protein responses in acinar cells-identified by 3D; all of them with a strong in silico functional support.
CONCLUSIONS: This multi-step strategy, combined with an in-depth in silico functional analysis, offers a comprehensive approach to advance the study of PC genetic susceptibility and could be applied to other diseases.
- 2006-0306: Whole Genome Scan of Incident Pancreatic Cancer in the Cohort Consortium (PanScan) (Rachael Stolzenberg-Solomon - 2006)